Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo.
Latest Information Update: 19 Dec 2022
Price :
$35 *
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart failure; Hypertension
- Focus Pharmacodynamics
- Acronyms eplerenone-01
- 19 Dec 2022 This trial has been completed in Netherlands , according to European Clinical Trials Database record.(Global end date 23 Dec 2013 )
- 30 Jan 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 31 Oct 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.